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LETTER TO THE EDITOR
Nitric oxide inhalation as an interventional 
rescue therapy for COVID-19-induced acute 
respiratory distress syndrome
Jun Kobayashi* and Isamu Murata
Abstract 
COVID-19 is an emerging disease of public health concern. While there is no specific recommended treatment for 
COVID-19, nitric oxide has the potential to be of therapeutic value for managing acute respiratory distress syndrome 
in patients with COVID-19. However, inhaled nitric oxide has not yet been formally evaluated. Given the extent of 
the COVID-19 pandemic, and the large numbers of hospitalized patients requiring respiratory support, clinical use of 
inhaled nitric oxide may become an alternate rescue therapy before extracorporeal membrane oxygenation for the 
management of acute respiratory distress syndrome in patients with COVID-19.
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Novel coronavirus disease 2019 (COVID-19) is an 
emerging disease of public health concern, and the cur-
rent pandemic is having a major global impact. Increas-
ing attention is being focused on the development of 
therapeutic strategies against this disease. We read, with 
great interest, the article by Li et al. “Therapeutic strate-
gies for critically ill patients with COVID-19” published 
in this journal [1]. While there is no specific recom-
mended antiviral treatment, and vaccines have yet to be 
developed, the authors provided a powerful pharmaco-
logical strategy for the treatment of critically ill patients 
with COVID-19 acute respiratory distress syndrome 
(ARDS). In this review article, the drug applications for 
COVID-19 are well described according to disease sever-
ity; however, nitric oxide (NO) inhalation therapy, which 
is not described in this review, may be included in the 
strategy as a promising therapeutic candidate. In 2004, 
during the severe acute respiratory syndrome coronavi-
rus (SARS-CoV) outbreak, a pilot study showed that low-
dose inhaled NO (max 30  ppm) could shorten the time 
of ventilatory support for patients infected with SARS-
CoV [2]. Although epidemiological evidence supporting 
the use of inhaled NO in treating COVID-19 has not yet 
been identified, similar therapeutic effects of NO can be 
expected for patients with COVID-19 due to the genetic 
similarities between the two viruses [3]. Based on this 
experience, clinical trials have begun in several medical 
institutes in the United States, and now a phase 2 clinical 
trial of inhaled NO is being conducted for mechanically 
ventilated patients with COVID-19 ARDS to confirm 
whether NO inhalation will become an interventional 
therapy to rescue patients with this disease [4].
The inflammatory cytokine storm induced by virus 
infection is closely related to the development and 
progression of ARDS. Given the common pathologi-
cal process leading to virus-induced ARDS [3], previ-
ous experience suggests that inhaled NO may be useful 
for managing COVID-19 ARDS. Previously published 
in  vitro studies indicated that NO possessed inhibitory 
effects on SARS-CoV replication. Moreover, growing evi-
dence has shown that inhaled NO can reduce inflamma-
tory cell-mediated lung injury by inhibiting neutrophil 
activation and subsequent pro-inflammatory cytokine 
release. Due to its potent and selective pulmonary vaso-
dilation, inhaled NO can lower pulmonary vascular 
resistance and decrease edema in the alveolar spaces, 
which enhances ventilation/perfusion matching. In addi-
tion, recent evidence also suggests that inhaled NO could 
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have a wide range of systemic effects via cGMP-depend-
ent and -independent mechanisms leading to a decrease 
in vascular tone, and a reduced risk of thrombosis and 
leukocyte adhesion to pulmonary and systemic vascular 
endothelium [5]. Because NO acts as a pro-inflamma-
tory and an anti-inflammatory agent, depending on the 
amount of NO generation and its source, early and timely 
initiation of inhaled NO therapy may prevent cytokine 
storms following abnormal vascular endothelium/leuko-
cyte interactions.
In severe COVID-19 ARDS with hypoxemia despite 
optimizing ventilation and other rescue strategies, extra-
corporeal membrane oxygenation (ECMO) is the final 
therapeutic option [1]. However, given the high running 
cost, limited number of devices, and the skilled medi-
cal staff required to perform ECMO, inhaled NO, which 
is relatively of low cost and readily available, may be a 
promising interventional therapy for patients with severe 
COVID-19 ARDS. Because inhaled NO has been exten-
sively applied to treat pulmonary hypertension, ARDS, 
and other respiratory diseases with a relatively good 
safety profile, we advocate for a clinical trial exploring 
the use of inhaled NO for the management of COVID-19 
ARDS to be conducted as a matter of urgency.
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